Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.

ABSTRACT:

SUBMITTER: Short NJ 

PROVIDER: S-EPMC11832082 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature